⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

Sarcoidosis is your immune system building tiny clusters called granulomas in one or more organs. It most often affects the lungs and the lymph nodes in the chest, but it can also involve the heart, nervous system, eyes, skin, liver, and other organs. It is not a cancer and it is not contagious.
Many people get better without any treatment. A large share of people — especially those with mild lung disease or with the acute form called Löfgren syndrome — improve on their own. Careful monitoring (“watchful waiting”) is an evidence-based choice, not “doing nothing.”
Treatment is reserved for symptoms or organ-threatening disease. The goal is to protect organ function and quality of life while avoiding medicines you do not need.
Diagnosis is a process of exclusion. Before settling on sarcoidosis, your team must rule out look-alikes — especially tuberculosis, fungal infections, a workplace exposure called chronic beryllium disease, and lymphoma.
Prednisone (a steroid) is usually the first medicine when treatment is needed — used at the lowest effective dose for the shortest time, because long-term steroids carry real side effects.
Steroid-sparing medicines like methotrexate are now used early. A 2025 clinical trial (PREDMETH) found methotrexate worked about as well as prednisone as a first treatment for lung sarcoidosis, with fewer ongoing side effects — a meaningful shift in care.
The heart deserves special attention. Heart involvement is uncommon but is one of the most dangerous forms. Palpitations, fainting or near-fainting, or new unexplained breathlessness should be reported promptly — these can be the first sign of cardiac sarcoidosis.
Fatigue is the most common and most disabling symptom — and it is real, even when scans look stable. It deserves attention in its own right.
For the minority whose lungs scar (fibrosis), an antifibrotic medicine (nintedanib) can slow decline, and advanced disease can be managed with oxygen, rehabilitation, and — when appropriate — lung transplant.
Be honest with yourself about the “cure” landscape. Promising targeted drugs have been tested, but the two most advanced recent trials (efzofitimod and namilumab) did not meet their main goals. Efzofitimod is still being developed in a redesigned phase 3, but nothing new is approved yet. That makes proven care — and good shared decision-making — more important than chasing the newest thing.

▼ Collapse

Understanding Sarcoidosis

Sarcoidosis (sar-koy-DOH-sis) is an inflammatory disease in which the immune system forms small clumps of inflammatory cells called granulomas. Under the microscope these are described as “noncaseating” granulomas, which simply means they do not have the cheesy dead center that tuberculosis granulomas typically have — a clue pathologists use to tell the two apart. Granulomas can form in almost any organ, but in more than 90% of people the lungs and the lymph nodes inside the chest are involved.

Why the immune system does this is still not fully understood. The leading idea is that in a genetically susceptible person, some trigger (perhaps an inhaled particle, a microbe, or another environmental exposure) sets off an exaggerated immune response that then does not switch off normally. Importantly, this means sarcoidosis is not something you caught from someone, did to yourself, or could have easily prevented.

The single most reassuring fact about sarcoidosis: for many people it is self-limiting. A substantial proportion of patients improve or fully remit on their own, often within 2–3 years, and never need long-term medication. The challenge is identifying the smaller group whose disease is progressive or organ-threatening — which is exactly what your specialist team is watching for.

The many faces of sarcoidosis

Because granulomas can appear in different organs, sarcoidosis looks very different from one person to the next:

Lungs and chest lymph nodes — the most common site. May cause cough, breathlessness on exertion, or chest discomfort — or no symptoms at all (often found incidentally on an X-ray).
Löfgren syndrome — an acute, dramatic-looking but generally favorable form: tender red bumps on the shins (erythema nodosum), swollen chest lymph nodes, and arthritis/fever. Most people with Löfgren syndrome recover fully.
Heart — uncommon but important; can cause rhythm problems, conduction block, or weakening of the heart muscle.
Nervous system (neurosarcoidosis) — can affect cranial nerves (e.g., facial weakness), the brain, the lining of the brain, or the spinal cord.
Eyes — inflammation inside the eye (uveitis) can threaten sight and sometimes appears before other symptoms.
Skin — ranges from erythema nodosum to a disfiguring purplish rash on the nose and cheeks called lupus pernio.
Liver, spleen, kidneys, bone marrow, muscles and joints — often silent, sometimes causing high blood calcium, kidney stones, or blood-count changes.

Who gets sarcoidosis?

Sarcoidosis occurs worldwide but varies by ancestry and region. It is more common — and tends to be more severe — in people of African ancestry, and it is also frequent in Northern Europe. Löfgren syndrome (the favorable acute form) is especially common in some European populations, such as Scandinavians. It most often appears between ages 20 and 60. Knowing these patterns helps your doctors anticipate risks, but your individual course is what matters most.

For lung sarcoidosis, doctors sometimes describe a chest X-ray “stage” using a system called the Scadding stages. This is a snapshot of the X-ray pattern — not a measure of how sick you are or a step-by-step progression like cancer staging:

Stage 0: normal chest X-ray.
Stage I: enlarged lymph nodes at the center of the chest (bilateral hilar lymphadenopathy), lungs clear. Often the most likely to resolve on its own.
Stage II: enlarged lymph nodes plus changes in the lung tissue.
Stage III: lung-tissue changes without the node enlargement.
Stage IV: scarring (fibrosis).

People can move between stages, stay the same for years, or improve. A “higher” number is associated with a somewhat lower chance of spontaneous resolution but does not dictate your future on its own.

What is sarcoidosis, and why is my immune system forming granulomas?
Which of my organs are involved, and how do you know?
Is my disease the acute kind (like Löfgren syndrome) that often gets better on its own, or a more chronic form?
What is my chest X-ray “stage,” and what does that mean for me specifically?
What is the realistic range of outcomes for someone with my pattern of disease?
Who will be on my care team, and which specialist coordinates everything?

For caregivers: Sarcoidosis is often an invisible illness — your person may look well while feeling exhausted or short of breath. One of the most valuable things you can do early is help keep an organized record: which organs are involved, which specialists are seeing them, what medicines they take, and what symptoms come and go. A simple shared note or folder pays off at every appointment.

How Sarcoidosis Is Diagnosed & When Treatment Is (and Isn’t) Needed

There is no single blood test that proves sarcoidosis. Instead, the diagnosis rests on three things coming together: (1) a clinical and imaging picture that fits, (2) a tissue sample (biopsy) showing noncaseating granulomas, and (3) the careful exclusion of other conditions that can look identical. Because of that third point, doctors call sarcoidosis a diagnosis of exclusion.

Why “ruling things out” matters so much. Tuberculosis and certain fungal infections form granulomas too — and treating those with immune-suppressing sarcoidosis medicines could be dangerous. So your team will work to exclude infection (and sometimes lymphoma or a beryllium exposure) before committing to the diagnosis and to treatment. This is a feature of good care, not unnecessary delay.

Do I need a biopsy?

Often yes — but not always. When a tissue sample is needed, the most common modern approach is a minimally invasive procedure called EBUS-TBNA (endobronchial ultrasound with a needle), in which a pulmonologist passes a thin scope into the airway and uses ultrasound to guide a tiny needle into chest lymph nodes. It is generally well tolerated and has a high success rate for finding granulomas.

There are important exceptions. If you have a classic presentation — especially Löfgren syndrome (erythema nodosum + symmetric chest node enlargement + arthritis/fever) — guidelines say a biopsy is often not required, because the picture is distinctive enough on its own.

What other tests to expect at diagnosis

Because sarcoidosis can be quietly active in organs you cannot feel, an initial “organ survey” is standard. Expect some combination of:

Breathing tests (pulmonary function tests) and a chest X-ray or CT scan.
An ECG (heart tracing) as a baseline screen for heart involvement — simple and important.
An eye exam to screen for uveitis, even if your eyes feel fine.
Blood tests including calcium (sarcoidosis can raise it), kidney and liver panels, and blood counts.

You may hear about a blood test called serum ACE (angiotensin-converting enzyme). It is frequently ordered, but it is not reliable enough to diagnose sarcoidosis or to track it precisely — many people with sarcoidosis have normal ACE, and other conditions can raise it. Treat it as one small piece of the puzzle, not the answer.

When is treatment needed — and when is watching the right move?

This is one of the most counterintuitive and important ideas in sarcoidosis care: not treating is frequently the correct, evidence-based decision. Because so many people improve spontaneously, medicines are generally reserved for:

Bothersome symptoms that affect daily life (e.g., significant cough or breathlessness), or
Organ-threatening disease — involvement of the heart, nervous system, eyes, kidneys, or progressive lung disease — where damage could be permanent.

If your disease is mild and not threatening any organ, your team may recommend active monitoring: periodic symptom checks, breathing tests, blood work (including calcium), and imaging. The plan is to step in if things change — and to spare you medication side effects in the meantime.

For caregivers: “Watchful waiting” can feel unsettling — like the doctors aren’t doing anything. It helps to reframe it: monitoring is the treatment plan for mild disease, and its whole purpose is to catch trouble early while avoiding harm. Help your person keep monitoring appointments and breathing tests, and flag new or worsening symptoms between visits.

Heart: palpitations (a racing, pounding, or skipping heartbeat), fainting or near-fainting, or new unexplained shortness of breath. Do not wait on these.
Eyes: eye redness, pain, light sensitivity, floaters, or any change in vision — uveitis can threaten sight and needs prompt care.
Lungs: a cough or breathlessness that is new, worsening, or not improving.
Nervous system: new facial weakness or droop, double vision, severe headache, numbness/tingling, or weakness.
General: profound fatigue with enlarged lymph nodes, unexplained weight loss, or drenching night sweats (the last two also warrant ruling out infection and lymphoma).

How confident are you in the diagnosis, and what other conditions did you rule out (TB, fungal infection, beryllium exposure, lymphoma)?
Did I need a biopsy, and if so, what did it show? If not, why was one not necessary?
Have we screened my heart (ECG) and eyes, and checked my calcium?
Do I need treatment now, or is monitoring the right choice for me? What would change that decision?
If we monitor, exactly which tests will we repeat, and how often?
What symptoms should make me call you sooner rather than wait for the next visit?

Steroids, Steroid-Sparing Medicines & Biologics

When treatment is needed, doctors think in terms of a flexible “ladder” — starting with what is most likely to help quickly and adding or switching agents to control disease while minimizing side effects. The ladder is not rigid; your team tailors it to which organs are involved and how you respond.

Step 1 — Glucocorticoids (prednisone)

Prednisone is the usual first medicine when treatment is indicated. It works reliably and relatively quickly to calm granulomatous inflammation. The catch is that prolonged steroid use causes real, cumulative side effects — weight gain, mood and sleep changes, higher blood sugar and blood pressure, bone thinning, cataracts/glaucoma, and infection risk. So the modern philosophy is: use the lowest dose that works, for the shortest time, and have a plan to taper.

A 2025 practice shift worth knowing. A randomized trial called PREDMETH (published in the New England Journal of Medicine) compared starting with methotrexate versus prednisone as the first treatment for pulmonary sarcoidosis. Over 24 weeks, methotrexate was about as effective at preserving lung function, with fewer side effects lingering at the end — though it works more slowly. For some people, starting with a steroid-sparing medicine instead of (or alongside a short course of) prednisone is now a reasonable, evidence-supported option to discuss.

Step 2 — Steroid-sparing medicines

These medicines let you control disease on a lower steroid dose — or sometimes no steroid. They generally act more slowly than prednisone (weeks to a few months), so they are often started while a steroid is still on board, then the steroid is tapered down.

Methotrexate — the most-used and best-studied second-line agent. Taken once weekly (with daily folic acid to reduce side effects). Requires periodic blood tests to monitor the liver and blood counts. Alcohol should be limited.
Azathioprine, leflunomide, mycophenolate — alternatives when methotrexate isn’t suitable or tolerated, each with their own monitoring.
Hydroxychloroquine — particularly useful for skin sarcoidosis and for high blood calcium; needs periodic eye exams.

Step 3 — Biologic therapy (anti-TNF)

For disease that does not respond to the medicines above — or for severe involvement of the skin, eyes, or nervous system — an intravenous biologic called infliximab (an anti-TNF antibody) is the option with the most evidence. Adalimumab is sometimes used as well. These are powerful and can bring stubborn sarcoidosis under control.

Before starting a biologic, screening is mandatory. Because anti-TNF drugs lower your defenses against certain infections, you will be tested for latent tuberculosis and hepatitis B/C first, and vaccinations are reviewed. Tell every provider you are on a biologic, and report fevers or infections promptly.

How the steps fit together

Think of it as: observe if you can → steroid if you must → add a steroid-sparing medicine early to get off the steroid → escalate to a biologic for refractory or severe disease. Many people never climb past the first or second rung. The aim throughout is the smallest amount of medicine that keeps your disease and symptoms controlled.

For caregivers — helping manage the medicines:

On prednisone: watch for mood swings, insomnia, increased appetite/weight, higher blood sugar (especially if diabetic), and stomach upset. Support bone health (calcium/vitamin D as advised — see the calcium caution below), and help keep eye-exam appointments (steroids can cause cataracts/glaucoma). Never stop steroids abruptly — they must be tapered.
On steroid-sparing medicines: help track the weekly methotrexate schedule (a common, dangerous error is taking it daily instead of weekly), keep up with monitoring blood tests, and have a reliable system for lab reminders.
On any immunosuppressant or biologic: be alert to infections — fever, productive cough, urinary symptoms, or skin infection deserve prompt attention. Keep vaccinations current as the team advises (generally avoiding live vaccines while immunosuppressed).

Sarcoidosis granulomas can convert vitamin D into its active form in an unregulated way, which can raise blood calcium and cause kidney stones or kidney injury. Because of this, people with sarcoidosis should be cautious about vitamin D and calcium supplements and high-calcium regimens unless specifically guided by their doctor. If your calcium is high, your team may recommend hydroxychloroquine or other steps, avoiding excess sun and supplements, and staying well hydrated. Always check before starting any vitamin D — what is healthy advice for the general public can be the wrong move in sarcoidosis.

If I need treatment, would you start with prednisone, a steroid-sparing medicine, or both — and why?
What dose of prednisone, and what is the taper plan? How will we limit side effects?
When would we add methotrexate (or another steroid-sparing medicine), and what monitoring does it need?
What would make you consider a biologic like infliximab, and what screening comes first?
Given the PREDMETH results, is starting with methotrexate a reasonable option for me?
What should I do about calcium and vitamin D — is it safe for me to take supplements?
Which side effects should I report right away versus mention at the next visit?

Heart, Nerve, Eye, Skin & Liver Involvement

Sarcoidosis can affect organs beyond the lungs. Some of these are mild; a few are serious and benefit from being caught early. This section walks through the most important ones — and what to watch for.

Heart (cardiac sarcoidosis) — uncommon but high-stakes

Granulomas in the heart can disturb its electrical wiring (causing abnormal rhythms or conduction block) or weaken the heart muscle. Cardiac sarcoidosis is one of the leading causes of serious outcomes in this disease, including sudden cardiac problems — which is exactly why doctors now look for it proactively.

The numbers have improved because detection and treatment have improved. A baseline ECG screens everyone. If heart involvement is suspected, specialized imaging — cardiac MRI and FDG-PET scanning — can find and characterize it. Treatment combines immunosuppression (to calm the inflammation) with cardiology care, which may include rhythm medicines and, when the risk of dangerous rhythms is high, an implantable defibrillator (ICD). A 2024 American Heart Association scientific statement reflects how much this field has matured.

Report immediately: palpitations, fainting or near-fainting, or new unexplained breathlessness. These are the symptoms that should never be brushed off.

Nervous system (neurosarcoidosis)

This can affect the cranial nerves (a common example is facial weakness), the brain and its lining, the pituitary gland, or the spinal cord. Because nerve tissue is delicate, neurosarcoidosis is usually treated aggressively — typically steroids combined with a stronger steroid-sparing medicine or a biologic (often methotrexate or infliximab) — to protect function.

Eyes (ocular sarcoidosis)

Inflammation inside the eye (uveitis) is common and can occasionally be the first sign of the disease. Untreated, it can threaten sight. The good news is that it responds well to prompt treatment — which is why a baseline eye exam is recommended even without eye symptoms, and why any eye redness, pain, light sensitivity, floaters, or vision change deserves a quick evaluation.

Skin (cutaneous sarcoidosis)

Skin disease ranges from the tender shin bumps of erythema nodosum (which usually heals) to lupus pernio, a persistent purplish thickening of the skin on the nose, cheeks, and ears that can be disfiguring and is often a marker of more chronic disease. Skin sarcoidosis is treated based on severity, from topical and antimalarial (hydroxychloroquine) therapy up to biologics for stubborn cases.

Liver, spleen, kidneys, and blood counts

These are often silent. Liver and spleen involvement may show up only on blood tests or imaging and frequently needs no specific treatment. Kidney issues are often tied to the high-calcium problem described earlier. Your routine blood work is partly there to keep an eye on all of this.

For caregivers — the heart is where vigilance matters most: Learn the three cardiac red flags by heart: palpitations, fainting/near-fainting, and new unexplained breathlessness. If your person faints or has a prolonged racing heartbeat, treat it as urgent. Also help them keep eye exams (for uveitis) and attend cardiology, neurology, and other specialist visits — multidisciplinary care is one of the biggest advantages in managing multi-organ sarcoidosis. Keeping a simple symptom log across organs helps the whole team spot patterns.

Have we checked my heart? If something looks off on my ECG, would I have a cardiac MRI or PET scan?
What heart symptoms should send me to urgent care or the emergency room?
Do I have any eye or nervous-system involvement, and how often should those be re-checked?
If my skin is involved, what are my options — and is lupus pernio a sign my disease may be more chronic?
Are my liver, kidney, and blood tests normal, and what would prompt action if they changed?
Which specialists should be part of my team, and who coordinates them?

Fatigue & Everyday Symptoms

If you remember one thing from this section: fatigue is the most common and most disabling symptom of sarcoidosis — and it is real. It can persist even when scans and breathing tests look stable, which sometimes leads to it being underestimated by others. You are not imagining it, and it deserves attention in its own right.

Why am I so tired? Sarcoidosis fatigue has several overlapping causes: the inflammatory disease itself, the effects of medications (steroids can disrupt sleep; some steroid-sparing agents cause fatigue or nausea), poor sleep, depression or anxiety that often accompany chronic illness, and sometimes a related nerve problem called small-fiber neuropathy (causing burning, tingling, or pain). Untangling the causes is the first step to addressing them.

What actually helps

Pacing and energy budgeting — planning demanding activities for your best hours and building in rest, rather than pushing to exhaustion.
Graded exercise and pulmonary rehabilitation — counterintuitively, supervised, gradually increasing activity is one of the better-supported approaches for sarcoidosis fatigue and breathlessness.
Sleep hygiene and screening for sleep apnea — which is common and very treatable.
Treating depression/anxiety — not because the fatigue is “in your head,” but because mood and energy are biologically linked and treating one helps the other.
Reviewing medications — sometimes adjusting a steroid dose or timing, or a steroid-sparing agent, makes a real difference.
Addressing small-fiber neuropathy — if burning/tingling is part of the picture, specific treatments exist.

Small-fiber neuropathy

Some people with sarcoidosis develop damage to the smallest nerve fibers, causing burning, tingling, numbness, or pain — and contributing to fatigue. Notably, this can occur even when standard tests look normal, so it can be missed. If this sounds like you, ask specifically about it; there are ways to evaluate and manage it.

For caregivers: Profound fatigue is hard for others to see and easy to underestimate. Believe it, and help your person pace rather than push — protecting energy for what matters most to them. Practical support (sharing chores on bad days, helping plan around peak-energy windows, encouraging gentle regular activity rather than boom-and-bust cycles) is genuinely therapeutic. And watch for low mood or withdrawal; depression is common in chronic illness and very treatable.

Could my fatigue be from the disease, my medications, poor sleep, mood, or a nerve issue — and how do we sort that out?
Would pulmonary rehabilitation or a graded exercise program help me?
Should I be screened for sleep apnea or for small-fiber neuropathy?
Are any of my medicines making the fatigue worse, and can we adjust them?
Can you connect me with support for the mental and emotional side of living with this?

Advanced Lung Disease & Living Well

Most people never reach advanced disease. But for the minority whose lungs scar over time, or who develop high blood pressure in the lung arteries, there are real, effective ways to slow decline and maintain quality of life.

Pulmonary fibrosis (lung scarring)

In a subset of people, chronic inflammation gives way to fibrosis — scarring that, unlike inflammation, does not reverse with immune-suppressing medicines. Recognizing when disease has shifted from “active inflammation” (which immunosuppression can help) to “scarring” (which it cannot) is an important judgment your team makes, sometimes with the help of imaging and PET scanning.

An antifibrotic option exists. For people with a progressive fibrosing pattern, a medicine called nintedanib (Ofev) can slow the decline in lung function. It was studied in a large trial (INBUILD) across many fibrotic lung diseases, including fibrotic sarcoidosis. It does not reverse scarring, and it has side effects (commonly diarrhea), but for the right person it is a meaningful tool.

Sarcoidosis-associated pulmonary hypertension (SAPH)

Some people develop high pressure in the blood vessels of the lungs, which can cause breathlessness out of proportion to other findings. This is evaluated by specialists (often with an echocardiogram and, when needed, a right-heart catheterization) and managed in specialized centers. Medicines used for other forms of pulmonary hypertension are sometimes tried, but the evidence in sarcoidosis is still limited, so this is best handled by an expert team.

Oxygen, rehabilitation, and transplant

Supplemental oxygen when blood oxygen runs low, to support activity and protect the heart.
Pulmonary rehabilitation — structured exercise and education that improves stamina, breathlessness, and quality of life.
Lung transplantation for carefully selected people with end-stage disease — an option that can extend and improve life when other measures are exhausted.

Living well across the whole journey

Bone protection if you are on steroids (your team will advise on monitoring and protective steps).
Vaccinations kept current per your team (important on immunosuppression; generally avoiding live vaccines while immunosuppressed).
Lung health — avoid smoking and secondhand smoke, and ask about indoor air quality and occupational exposures.
Mental health — an unpredictable, invisible illness takes a psychological toll; support is part of good care, not a luxury.

Can I get pregnant?

Many people with sarcoidosis have healthy pregnancies, and for some, disease activity even quiets during pregnancy. However, some medications used in sarcoidosis are not safe in pregnancy (methotrexate, leflunomide, and mycophenolate must be stopped and avoided), while others can be continued under guidance. If you are considering pregnancy, plan ahead with your team so your regimen can be adjusted safely before conception, and so any heart or lung involvement is assessed.

For caregivers: In advanced disease, your role often expands — coordinating oxygen, helping with rehabilitation, attending transplant evaluations, and providing steady emotional support through uncertainty. Take care of your own wellbeing too; caregiver burnout is real, and you are most helpful when you are also supported. Ask the care team about caregiver resources and respite options.

Is my lung disease mostly active inflammation (treatable with immunosuppression) or scarring (fibrosis)?
Am I a candidate for an antifibrotic medicine like nintedanib?
Should I be evaluated for pulmonary hypertension, and at a specialized center?
Would oxygen or pulmonary rehabilitation help me now?
If my disease became end-stage, when would we talk about lung transplant evaluation?
If I want to become pregnant, how should we adjust my medications and timing?
What bone protection, vaccinations, and lifestyle steps do you recommend for me?

class="content-section" data-stage="research,trials">

Clinical Trials & New Treatments — an Honest Look

Sarcoidosis research is active, and clinical trials are a reasonable thing to ask about. But you deserve a clear-eyed picture rather than hype — especially because the two most advanced recent drug trials did not succeed. Here is where things genuinely stand.

The big recent news is sobering but honest. Two targeted medicines reached late-stage trials and were widely hoped to become the first new sarcoidosis-specific therapies in decades. Both missed their main goals:

Efzofitimod (the EFZO-FIT phase 3 trial, NCT05415137) did not meet its primary endpoint of reducing steroid use, reported in September 2025. Some secondary measures (quality of life, complete steroid withdrawal, fatigue) looked favorable at the higher dose. After an FDA meeting in April 2026, the company announced in May 2026 that it plans to run a new phase 3 trial — this time in people with chronic, symptomatic pulmonary sarcoidosis who have stiff (restrictive) lungs, using lung function (forced vital capacity, FVC) as the main goal. So the drug is still being developed, but it remains investigational, is not approved or proven, and any possible approval is still years away.
Namilumab (the RESOLVE-Lung phase 2 trial, NCT05314517) also failed its primary endpoint, reported in December 2024, and its development for sarcoidosis was discontinued.

Why share disappointing results? Because honesty protects you. Anyone promising a “breakthrough cure” based on these drugs is ahead of the evidence.

What did move care forward recently

PREDMETH (NCT04314193, NEJM 2025) — showed methotrexate can be a reasonable first-line alternative to prednisone for lung sarcoidosis, with fewer lingering side effects. This is a real, practice-relevant advance.
Better heart care — a 2024 American Heart Association scientific statement consolidated how to detect and manage cardiac sarcoidosis.

What is still being studied

JAK inhibitors (such as tofacitinib) — oral medicines targeting an inflammatory pathway active in sarcoidosis. Early studies and many case reports show promise, especially for stubborn skin disease; they are used off-label in some refractory cases and are being studied further. Not yet approved for sarcoidosis.
Other agents — an anti-TNF antibody (XTMAB-16) completed enrollment in an early trial; agents targeting other inflammatory signals have been tested with mixed results; inhaled treprostinil is studied for sarcoidosis-associated pulmonary hypertension. These remain investigational.
Better measurement tools — research into PET imaging and biomarkers aims to better separate active inflammation from old scarring, to guide who needs treatment.
Fatigue and quality of life — studies are testing exercise programs and other approaches because fatigue matters so much day to day.

How to find and evaluate a trial

Search ClinicalTrials.gov (the official U.S. registry) for “sarcoidosis” plus your organ or city.
Ask your sarcoidosis specialist or a center of excellence — many trials run only at specialized centers.
The Foundation for Sarcoidosis Research maintains trial information and patient resources.
For any trial, ask: What is being tested and why? What are the risks and the time commitment? Could I get a placebo? Who covers costs? What happens when the trial ends?

Honesty about what does not work is as important as knowing what does:

Efzofitimod and namilumab — as above, both missed their primary endpoints in recent trials. Treat “miracle new sarcoidosis drug” claims with skepticism.
Etanercept — another anti-TNF drug — performed poorly for sarcoidosis in studies, unlike infliximab. Not all drugs in a class work the same way.
Antibiotic “CLEAR”-type regimens — combination antimicrobial protocols have been explored based on the theory that microbes trigger sarcoidosis, but they are not established standard care; evidence is limited.
Supplements and “immune-boosting” protocols — there is no supplement proven to treat sarcoidosis, and some (especially vitamin D and calcium) can be actively harmful by worsening high calcium. Always clear supplements with your team.
Cannabis/CBD as a disease treatment — may help some symptoms for some people, but there is no evidence it treats the underlying disease; discuss interactions and risks.

None of this is a substitute for evaluation and care by a qualified clinician.

Are there clinical trials that fit my type of sarcoidosis, and would you recommend one for me?
What do you make of the efzofitimod and namilumab trial results — do they change anything for me?
Is an off-label JAK inhibitor ever appropriate for my situation (for example, stubborn skin disease)?
How do we tell whether my lung changes are still “active” (treatable) or scarring?
I read about a treatment online — is there real evidence behind it, or is it a claim to be cautious about?

Specialty Centers, Access & Support

Multidisciplinary care — pulmonology working alongside cardiology, neurology, ophthalmology, rheumatology, and others — is one of the biggest advantages in managing a multi-organ disease like sarcoidosis. Below are resources, starting close to home for readers in the Mountain West.

Mountain West & Utah

University of Utah Health (Salt Lake City) — multidisciplinary sarcoidosis-relevant care across pulmonary/interstitial lung disease, rheumatology, cardiology (cardiac-sarcoidosis evaluation with MRI/PET and electrophysiology), neurology, and the John A. Moran Eye Center for uveitis; infliximab infusion services and clinical trials. Main line: 801-581-2121.
Intermountain Health (Wasatch Front and across Utah) — pulmonology and multidisciplinary clinics for diagnosis, pulmonary function testing, immunosuppression management, and infusion services. Find a provider: 801-442-5000 (Intermountain Medical Center, Murray).
George E. Wahlen VA Medical Center (Salt Lake City) — pulmonary and multisystem sarcoidosis care for veterans. Main line: 801-582-1565.
Infusion centers & specialty pharmacies (University of Utah, Intermountain) — administer infliximab and help coordinate specialty-drug approvals and patient-assistance programs.

U.S. national centers of excellence (illustrative)

Several academic centers have dedicated sarcoidosis or interstitial lung disease programs with deep experience in cardiac and neurologic disease. Examples frequently cited include the Cleveland Clinic, Johns Hopkins, University of Cincinnati, National Jewish Health (Denver), Mount Sinai (New York), and Mayo Clinic. The Foundation for Sarcoidosis Research can help you locate specialists; ask your insurer about in-network options and any referral requirements before traveling.

Veterans

Sarcoidosis is recognized within the VA system, and veterans should ask about service connection if their diagnosis may relate to military exposures (for some veterans, sarcoidosis has been considered presumptively connected to certain service circumstances — eligibility rules change, so ask a Veterans Service Officer). The Salt Lake City VA and the broader VA pulmonary network can coordinate care.

Canada

Care is delivered through provincial health systems and academic respirology programs (for example, in Toronto, Montreal, and Vancouver). Biologics and antifibrotics may require special authorization through provincial drug plans; ask your respirologist about coverage pathways and timelines.

International

Notable specialized centers include St. Antonius Hospital (Nieuwegein, Netherlands), Royal Brompton Hospital (London, UK), and academic centers across France, Germany, Italy, Spain, and Japan (the latter with particular cardiac-sarcoidosis expertise). The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is a useful starting point.

Education, peer support & assistance

Foundation for Sarcoidosis Research (FSR) — stopsarcoidosis.org — education, peer-support communities, trial information, and financial-assistance and fatigue resources.
American Lung Association — lung.org — general lung-health education and support.
ClinicalTrials.gov — the official registry of clinical trials.

For caregivers: If your person’s care is scattered across specialists, ask whether a single sarcoidosis or ILD clinic can coordinate — it reduces conflicting advice and dropped balls. Keep a one-page summary (diagnosis, organs involved, current medicines and doses, allergies, key contacts) to bring to every visit and any ER trip. For biologics and antifibrotics, specialty pharmacies and manufacturer patient-assistance programs can substantially reduce cost — ask the infusion center or pharmacist to help you apply.

Which treatments are available — and approved — varies by country:

Prednisone and other steroids — available essentially everywhere; the universal first-line when treatment is needed.
Methotrexate, azathioprine, leflunomide, mycophenolate, hydroxychloroquine — widely available, but mostly used off-label for sarcoidosis (approved for other conditions). This is normal and evidence-based, even without a sarcoidosis-specific label.
Infliximab / adalimumab (biologics) — available in most developed health systems, but used off-label for sarcoidosis and often requiring prior authorization. Access and cost vary widely.
Nintedanib (Ofev) — approved (US FDA, EMA in Europe, others) for progressive fibrosing interstitial lung disease, which can include fibrotic sarcoidosis — though coverage rules differ by country and payer.
Repository corticotropin (H.P. Acthar Gel) — a U.S.-specific FDA-approved option for symptomatic sarcoidosis; rarely used elsewhere, expensive, and with limited modern trial evidence.
Efzofitimod — not approved anywhere; investigational. It missed its main phase 3 goal in 2025; a redesigned phase 3 (FVC endpoint, restrictive disease) was announced in May 2026.
Regional emphasis — in countries with high tuberculosis or endemic fungal infection (much of South Asia, parts of Africa, Latin America), ruling out infection before diagnosing sarcoidosis is an even more central step. Japan has historically led in cardiac-sarcoidosis recognition.

Should I be seen at a specialized sarcoidosis or ILD center, and can you refer me?
Who coordinates my care across specialists?
If I need a biologic or antifibrotic, how do we handle insurance approval and cost?
Are there patient-assistance programs I qualify for?
Can you connect me with a peer-support community or the Foundation for Sarcoidosis Research?

Glossary & Key Sources

Granuloma — a small cluster of immune cells; the building block of sarcoidosis.
Noncaseating granuloma — a granuloma without a dead, cheese-like center; the type seen in sarcoidosis (helps distinguish it from TB).
Diagnosis of exclusion — a diagnosis made only after ruling out look-alike conditions.
Löfgren syndrome — an acute form (shin bumps + chest node enlargement + arthritis/fever) with a generally good outlook.
Scadding stage — a chest X-ray pattern (0–IV), not a severity score.
EBUS-TBNA — a minimally invasive scope-and-needle procedure to biopsy chest lymph nodes.
Glucocorticoid / prednisone — a steroid anti-inflammatory medicine; usual first treatment.
Steroid-sparing agent — a medicine (e.g., methotrexate) used to control disease while lowering steroid dose.
Biologic / anti-TNF — a targeted antibody medicine (e.g., infliximab) for refractory/severe disease.
Uveitis — inflammation inside the eye; can threaten vision.
Lupus pernio — a persistent purplish facial skin form of sarcoidosis.
Cardiac sarcoidosis — heart involvement; can cause dangerous rhythm problems.
Neurosarcoidosis — nervous-system involvement.
Fibrosis — scarring; does not reverse with immune-suppressing medicines.
Antifibrotic (nintedanib) — a medicine that can slow progressive lung scarring.
SAPH — sarcoidosis-associated pulmonary hypertension (high pressure in lung arteries).
Small-fiber neuropathy — damage to the smallest nerves causing burning/tingling and fatigue.
Serum ACE — a blood test sometimes ordered in sarcoidosis but not reliable for diagnosis or tracking.

ATS 2020 Diagnosis & Detection of Sarcoidosis (official ATS clinical practice guideline). Crouser ED, et al. Am J Respir Crit Care Med 2020;201(8):e26–e51.
ERS 2021 Clinical Practice Guidelines on Treatment of Sarcoidosis. Baughman RP, Valeyre D, Korsten P, et al. Eur Respir J 2021;58:2004079.
PREDMETH trial (methotrexate vs prednisone first-line). Kahlmann V, et al. N Engl J Med 2025;393(3):231–242. ClinicalTrials.gov NCT04314193.
Infliximab in pulmonary sarcoidosis (randomized trial). Baughman RP, et al. Am J Respir Crit Care Med 2006;174:795–802.
Nintedanib in progressive fibrosing ILD (INBUILD). Flaherty KR, et al. N Engl J Med 2019;381:1718–1727. NCT02999178.
HRS 2014 expert consensus on cardiac sarcoidosis. Birnie DH, et al. Heart Rhythm 2014;11:1305–1323; and the 2024 AHA Scientific Statement on cardiac sarcoidosis (Circulation).
Efzofitimod EFZO-FIT phase 3 topline results (missed primary endpoint), aTyr Pharma, September 2025; FDA Type C meeting and new phase 3 (FVC endpoint) announced May 2026. NCT05415137.
Namilumab RESOLVE-Lung phase 2 topline results (missed primary endpoint), Kinevant/Roivant, December 2024. NCT05314517.
Foundation for Sarcoidosis Research (stopsarcoidosis.org) and American Lung Association (lung.org).

Important. This guide is educational and does not replace personalized medical advice. Sarcoidosis is highly variable, evidence is still evolving, and decisions should be made with your own care team, who know your full situation.